Alliance Pharma PLC
LSE:APH
Intrinsic Value
Alliance Pharma Plc is a holding company, which engages in the acquisition, marketing, and distribution of healthcare and pharmaceutical products. [ Read More ]
The intrinsic value of one APH stock under the Base Case scenario is 101.99 GBX. Compared to the current market price of 34.75 GBX, Alliance Pharma PLC is Undervalued by 66%.
Valuation Backtest
Alliance Pharma PLC
Run backtest to discover the historical profit from buying and selling APH stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Alliance Pharma PLC
| Current Assets | 94.7m |
| Cash & Short-Term Investments | 26.1m |
| Receivables | 39.3m |
| Other Current Assets | 29.3m |
| Non-Current Assets | 419.1m |
| PP&E | 5.3m |
| Intangibles | 409.6m |
| Other Non-Current Assets | 4.2m |
| Current Liabilities | 49m |
| Accounts Payable | 14.1m |
| Accrued Liabilities | 16.5m |
| Other Current Liabilities | 18.4m |
| Non-Current Liabilities | 187.7m |
| Long-Term Debt | 123.7m |
| Other Non-Current Liabilities | 64m |
Earnings Waterfall
Alliance Pharma PLC
|
Revenue
|
170m
GBP
|
|
Cost of Revenue
|
-72.1m
GBP
|
|
Gross Profit
|
97.9m
GBP
|
|
Operating Expenses
|
-91.7m
GBP
|
|
Operating Income
|
6.2m
GBP
|
|
Other Expenses
|
-13.3m
GBP
|
|
Net Income
|
-7.1m
GBP
|
Free Cash Flow Analysis
Alliance Pharma PLC
APH Profitability Score
Profitability Due Diligence
Alliance Pharma PLC's profitability score is 52/100. The higher the profitability score, the more profitable the company is.
Score
Alliance Pharma PLC's profitability score is 52/100. The higher the profitability score, the more profitable the company is.
APH Solvency Score
Solvency Due Diligence
Alliance Pharma PLC's solvency score is 39/100. The higher the solvency score, the more solvent the company is.
Score
Alliance Pharma PLC's solvency score is 39/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
APH Price Targets Summary
Alliance Pharma PLC
According to Wall Street analysts, the average 1-year price target for APH is 68.78 GBX with a low forecast of 42.42 GBX and a high forecast of 105 GBX.
Shareholder Return
APH Price
Alliance Pharma PLC
| Average Annual Return | -1.36% |
| Standard Deviation of Annual Returns | 33.21% |
| Max Drawdown | -71% |
| Market Capitalization | 189.1m GBX |
| Shares Outstanding | 541 576 000 |
| Percentage of Shares Shorted | 98% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Alliance Pharma Plc is a holding company, which engages in the acquisition, marketing, and distribution of healthcare and pharmaceutical products. The company is headquartered in Chippenham, Wiltshire and currently employs 255 full-time employees. The company went IPO on 2001-11-22. The firm is primarily engaged in the acquisition, marketing and distribution of healthcare and pharmaceutical products. The company is focused on two areas, which include Consumer Healthcare brands and Prescription Medicines. The Company’s Consumer Healthcare brands include Kelo-Cote, Nizoral, Amberen, MacuShield, Vamousse and Aloclair. Its Prescription Medicines include Hydromol, Flamma Franchise and Forceval. Its brands also include Ashton & Parsons and Anbesol. The Company’s products include Alliance Calcium Syrup, Amantadine hydrochloride, Aiweidi, Biodermatin, Biotaches, Buccastem M, Changmin, Decapional, Dermachronic, Dermacide, Dervida, Effadiane, Fazol, Gen-Ongles, Irenat, ISIB, Isocarboxazid, Jonctum, Kelo-Stretch, Lypsyl, Lefuzhi, Malunjunshe, MolluDab, Menadiol, Neostigmine and Nu-Seals. Its geographical area includes Europe, Middle East and Africa (EMEA), Asia Pacific and China (APAC) and Americas (AMER).
Contact
IPO
Employees
Officers
The intrinsic value of one APH stock under the Base Case scenario is 101.99 GBX.
Compared to the current market price of 34.75 GBX, Alliance Pharma PLC is Undervalued by 66%.
You don't have any saved screeners yet
